Chapter 2 - University of British Columbia
Chapter 2 - University of British Columbia
Chapter 2 - University of British Columbia
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
was identified in a small set <strong>of</strong> samples, we wanted to see if this prevalence <strong>of</strong> disruption was<br />
maintained in an additional, larger set <strong>of</strong> tumors. Hence, we evaluated expression <strong>of</strong> SHP-1<br />
and SIRPA in a panel <strong>of</strong> approximately 60 lung adenocarcinoma tumors and found (i) a high<br />
prevalence <strong>of</strong> underexpression <strong>of</strong> SIRPA and (ii) a strong correlation between SIRPA and SHP-<br />
1 expression levels. It is interesting to observe this strong relationship between SIRPA and<br />
SHP-1 as most cancer studies have focused on SIRPA’s relationship with SHP-2 instead <strong>of</strong><br />
SHP-1.<br />
6.2 Conclusions<br />
I have demonstrated the power <strong>of</strong> an integrative genetic and epigenetic approach to decipher<br />
resultant gene expression changes in lung adenocarcinoma. The development <strong>of</strong> an<br />
application such as SIGMA2 was integral as it represented one <strong>of</strong> the first academic/research<br />
applications with the ability to integrate multiple dimensions <strong>of</strong> data. To date, there have been a<br />
few other applications that have been developed that can perform similar functionalities but<br />
most <strong>of</strong> these have been developed by commercial entities. Moreover, the s<strong>of</strong>tware still is not<br />
out-dated and based on the way it was built, can be extended to handle newer high throughput<br />
platforms including sequence-based platforms.<br />
In terms <strong>of</strong> what we learn from both the demonstration dataset (<strong>Chapter</strong> 3) as well as clinical<br />
tumor dataset (<strong>Chapter</strong> 5), we know that by using an integrative, multi-dimensional approach,<br />
we are detecting genes being disrupted at a much higher frequency when multiple dimensions<br />
are examined as compared to single dimensions alone. Moreover, at a given detection<br />
frequency, a gene may be disrupted by a single dimension at a low frequency but when multiple<br />
dimensions are accounted for, the frequency is in fact high. In Figure 5.5, I illustrate how well<br />
known lung cancer genes such as RRM2 are altered at both the genetic and epigenetic level<br />
and illustrate how more pathways are deemed significant when multiple dimensions are<br />
analyzed. The latter finding is likely a result <strong>of</strong> the fact that within a given pathway, not only can<br />
different genes be affected in different samples by one mechanism (e.g. DNA copy number<br />
166